Alzheimer's disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer's disease-even for people with no sign of cognitive decline.
[More]
Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found. People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer's disease compared with those who have other variations of the gene.
[More]
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
[More]
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.
[More]
Sam Gandy, MD, PhD, of the Icahn School of Medicine at Mount Sinai is leading an international team of researchers working to reprogram skin cells into brain cells to gain a better understanding of Alzheimer's disease.
[More]
A study in the JAMA Neurology (formerly the Archives of Neurology) suggests that controlling or preventing risk factors such as hypertension earlier in life may limit or delay the brain changes associated with Alzheimer's disease and other age-related neurological deterioration.
[More]
WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).
[More]
Researchers have identified a possible treatment window of several years for plaques in the brain that are thought to cause memory loss in diseases such as Alzheimer's. The Mayo Clinic study is published in the Feb. 27 online issue of Neurology, the medical journal of the American Academy of Neurology.
[More]
A study combining genetic data with brain imaging, designed to identify genes associated with the amyloid plaque deposits found in Alzheimer's disease patients, has not only identified the APOE gene -- long associated with development of Alzheimer's -- but has uncovered an association with a second gene, called BCHE.
[More]
A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.
[More]
Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.
[More]
Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.
[More]
Two studies in people at genetic risk for Alzheimer’s disease reveal very early changes in brain structure and function that may actually precede amyloid beta deposition.
[More]
Using solid-state nuclear magnetic resonance (NMR) spectroscopy, researchers at Luleå University of Technology in collaboration with Warwick University in the UK for the first time in the world managed to analyse hydrogen bonds in tiny fibrils of Amyloid-beta peptide , which probably causes Alzheimer's disease.
[More]
A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.
[More]
It was clear from the title – Dementia: A National Crisis – that the conference would focus on the important challenges facing many people living with dementia in the country today.
[More]
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).
[More]
The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.
[More]
Living subjects are very complex systems and, at the same time, stunningly robust and accommodative. The secret of success are their proteins which build up the cells of the organisms, act as cleaners, messengers, transporter, motors, and fulfill much more jobs. How proteins are genetically coded and how their linear chains of amino acids are put together, is in principle well known.
[More]
Advanced Radiology, a division of RadNet, Inc., a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 237 fully-owned and operated outpatient imaging centers, announced it will be one of a small number of imaging centers in the U.S. to offer Amyvid, a radioactive tracer used in positron emission tomography – computed tomography (PET/CT) imaging that helps to detect the quantity of beta-amyloid plaque in patient's brains.
[More]